Acquisition of 2 packages of brands in our international operations Entrance to IPC Sustainability Index and MSCI Index Acquisition of the brands: Fermodyl, Zan Zusi, Altiva, Amara, Larizá, Bioskin and XL-3 in Mexico, Babysan and Piecidex in Argentina and Dermaglós in Brazil Acquisition of Marzam Acquisition of the brands Nasalub, Micotex, Ossart, English Leather, Galaflex, Affair and Santé Acquisition of Tafirol in Argentina, and Losec and Launch of Primer Nivel, Genomma package of OTC brands in Lab’s Branded Generics Line Mexico Expanded product portfolio through development of new Acquisition of the brands Vanart, products and line extensions Pomada de la Campana, Wildroot, Alert and Nórdiko Changed Business Expanded management Model to OTC/PC team With the launch of operations in Brazil and Organic growth through brand and USA, Genomma has operations in 14 product development countries Founded as an Acquisitions of Medicinas y Medicamentos infomercial marketing Nacionales, Jockey Club, Flor de Naranja company Sanborns, Teatrical and Henna Egipcia Performed its IPO in the Mexican Stock Market Nexxus Capital invested 30% of Equity
• ῀ • • • ῀ •
Best formulation and Performance presentation Analysis (Product Selection) MANUFACTURING DEVELOPMENT INNOVATION & MARKETING & OUTSOURCED DISTRIBUTION ASSURANCE BRANDING QUALITY SALES Impressively short lead time Rapid and effective from an idea generation to new reaction to competitive product launches and line challenges extensions. Pillars
Focuses on topical Offers branded OTC Offers over 100 dermatological, facial SKU’s pharmaceuticals in under the and hair treatments variety of forms brand Primer Nivel and other categories Por Tu Salud - Inhibitors of gastric - Varicose vein secretions - Anti-rheumatics treatment - Hemorrhoid - Anti-ulcer drugs - Scar removal treatment - Anti-histamines - Face and body - Anti-flu - Anti-micotics lotions - Anti-acne - Anti-fungals
Genomma's core asset is its portfolio of market leading brands. As of September 2014, the Company has a total of 91 brands . The following table shows the Company’s top 25 brands for the last twelve months as of September 2014, which represented 82.1% of Total Sales. Sexual Protection and Anti-scar, Anti-wrinkle Enhancement Anti-acne Colitis Treatment Spider Vein Treatment Osteoarthritis Treatment Athlete’s Foot Treatment Hair Care Baldness Treatment Cough Syrup Anti-flu Analgesic Anti-micotic Gastritis Treatment Anti-flu Weight Control Treatment Anti-dandruff Shampoo Pain Relief Vitamins Shampoo Shampoo Headache Treatment Hemorrhoid Treatment Hair Care Cervical Infections Treatment
Demand for our products is mainly generated through advertising. We have a directed advertising strategy, based on metric analyses of our clients and the market. We monitor such information weekly, which allows us to have a quick response to changes in competition and consumer’s preferences.
(For the last twelve months, as of September 2014) Genomma Lab Bayer Boehringer Sanofi Aventis Shering Plough Pisa Reckitt Benckiser Novartis Wyeth Johnson Johnson Source: IMS Health.
Source: Company data and IMS Health.
Source: Company data and IMS Health..
OTC – Over the Counter Pharma – OTC and Generics PC – Personal Care 1. Brazil 2. Argentina 3. USA 4. Colombia 5. Chile 6. Peru 7. Ecuador *According to IMS.
*As of September 2014 (LTM)
Bolivia Chile Costa Rica Brands: 19 Dominican Republic Ecuador El Salvador Guatemala Honduras Brands: 91 Nicaragua Brands: 13 Panama Paraguay Peru Uruguay Brands: 26 Brands: 12 Brands: 25
• • Innovation & Development Entrance to new segments • • Broad Distribution Formula Improvement • • Line Extensions Revitalize Acquired Brands • • Brand Development Implement Marketing Capabilities • International Expansion
*CAGR from 2008 to 2013 2008 2009 2010 2011 2012 2013 3Q14 LTM
Nasal Hygiene Nasalub Max For adults For children Vitamins Energetic beverage Vitamins for with vitamins children
X-Ray with added Calcium and Vitamin D Osteoarthritis treatment for diabetics Osteoarthritis Joint pain treatment relief
YoY Growth: 9.5% 2008 2009 2010 2012 2013 2011 3Q13 3Q14 3Q14 3Q13 Pharma* PC Total 3Q14 Pharma* PC Total 3Q13 %Var Mexico 1,339.0 675.6 2,014.6 1,197.7 819.4 2,017.1 -0.1% International 379.0 966.0 1,344.9 240.2 809.4 1,049.6 28.1% TOTAL 1,718.0 1,641.5 3,359.5 1,437.9 1,628.8 3,066.8 9.5%
3,500 50.0% 3,000 YoY Growth: 2,500 40.0% 6.8% 2,000 30.0% 1,500 20.0% 1,000 10.0% 500 - 0.0% 2008 2009 2010 2012 2013 2011 3Q13 3Q14 EBITDA EBITDA MARGIN
1Q12 2Q12 3Q12 4Q12 1Q13 2Q13 3Q13 4Q13 1Q14 2Q14 3Q14
YoY Growth: 1.3% 2008 2009 2010 2012 2013 2011 3Q13 3Q14 NET INCOME AS % OF REVENUE
@
Recommend
More recommend
